Journal
CYTOTHERAPY
Volume 19, Issue 10, Pages 1225-1232Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2017.07.008
Keywords
aNK cells; NK-92 cell line; acute myeloid leukemia; immune effects; immunotherapy; phase 1
Categories
Funding
- National Heart, Lung, and Blood Institute [NHLB1-N01 HB37163]
- NantKwest, Inc.
Ask authors/readers for more resources
Background aims. Activated NK cells (aNK) generated by expansion of a human interleukin-2-dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity. This phase 1 study evaluated feasibility, safety, and activity of aNK cells adoptively transferred to patients with refractory/relapsed acute myeloid leukemia (AML). In addition, effects of these aNK cells on the patient's immune system were evaluated. Methods. Two cell-dose levels (1 x 10(9) cells/m(2) and 3 x 10(9) cells/m(2)) were used. One treatment course consisted of two infusions of the same cell dose, each cell infusion delivered 24 h apart. The aNK cells were administered in the outpatient setting. Results. Seven patients with refractory/relapsed AML were treated with a total of 20 aNK cell infusions. None of the 7 patients experienced dose-limiting toxicities during the aNK cell administration or during 21 days of the post-infusion observation period. No grade 3-4 toxicities (probable or definite) related to aNK cell infusions occurred. Activity was transient in 3 of 7 patients. No significant changes in the patient's lymphocyte counts, subsets frequency, phenotype or activity were observed post-infusion. Cell dose-dependent effects in the plasma levels of several cytokines were observed. Discussion. The trial demonstrated the safety and feasibility of adoptive cell therapy with off-the-shelf aNK cells in patients with refractory/relapsed AML. These data provide the foundation for future combination immunotherapy trials and for the optimization of aNK cell based therapies in patients with AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available